Skip to main content
Premium Trial:

Request an Annual Quote

Michael Murphy, Sandra Foster, Michael Reinemann

Akonni Biosystems has appointed Michael Murphy as VP of regulatory affairs, Sandra Foster as director of quality assurance, and Michael Reinemann as director of business development. Murphy joins Akonni from Conatus Consulting, a regulatory consulting practice, where he served as president for seven years. He has also held executive management positions at ParagonDx, PPGx, Clingenix, and Gentris. Foster joins Akonni from her own private consulting company, Triangle GxP Solutions. She has also spent 12 years in various clinical-phase biotechnology companies. Reinemann joins Akonni from Qiagen, where he held various commercial operations roles, including regional marketing manager of North America and senior global product manager.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.